Description

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), consisting of 30 amino acids with modifications for enhanced stability and resistance to enzymatic degradation (e.g., by dipeptidyl peptidase-4 or DPP-4). It stimulates the pituitary gland to release endogenous human growth hormone (hGH) in a more sustained and physiological manner compared to native GHRH.

There are two main variants:

• CJC-1295 without DAC (often called Modified GRF 1-29 or CJC-1295 no DAC): Shorter-acting form with a half-life of about 30 minutes to a few hours, promoting more natural, pulsatile GH release similar to the body’s rhythm.
• CJC-1295 with DAC (Drug Affinity Complex): Longer-acting version where a DAC molecule is added to bind to albumin in the blood, extending the half-life to 6–8 days for prolonged, steady GH and IGF-1 elevation.

CJC-1295 is not FDA-approved as a therapeutic drug (as of March 2026). It remains available primarily through research peptide suppliers or compounding pharmacies (with a prescription) for off-label use in wellness, anti-aging, performance, or hormone optimization protocols. Regulatory status for compounding has been in flux (e.g., past Category 2 restrictions on some peptides, with ongoing reviews and potential shifts in 2026), so availability and legality vary—always check with a healthcare provider.

Key Features and Mechanism of Action

CJC-1295 binds to GHRH receptors on the pituitary:

• Triggers increased secretion of hGH, leading to elevated IGF-1 (insulin-like growth factor-1) from the liver.
• Supports downstream effects like protein synthesis, lipolysis (fat breakdown), and tissue repair.
• With DAC: Provides sustained elevation (cumulative IGF-1 effects lasting weeks after multiple doses in studies).
• Without DAC: Better mimics natural GH pulses, often preferred when stacked with a GHRP like Ipamorelin for synergy (Ipamorelin provides rapid pulses, CJC-1295 extends them).

This results in physiological GH restoration, especially useful for age-related decline, without the broad suppression or supraphysiological spikes seen with direct hGH injections.

Potential Benefits

From clinical observations, off-label use, and studies (strongest evidence from early trials and animal/preclinical data):

• Body Composition: Increased lean muscle mass/strength, enhanced fat loss (especially visceral), improved metabolism.
• Recovery and Repair: Faster healing from injuries/exercise, better joint/bone health, reduced inflammation.
• Anti-Aging/Wellness: Improved skin elasticity, energy/vitality, sleep quality, immune function, and overall metabolic/cardiovascular support.
• Other Areas: Potential for better libido, cognitive aspects (via IGF-1), and adjunctive roles in performance or regenerative protocols (often stacked with Ipamorelin for amplified effects).

Administration and Dosing

• Primary Route: Subcutaneous injection (reconstituted from lyophilized powder with bacteriostatic water).
• Typical Research/Compounded Dosing (from protocols and reports; not medical advice):
  • Without DAC: 100–300 mcg per dose, 1–3 times daily (e.g., bedtime or post-workout) to align with natural pulses.
  • With DAC: 1–2 mg once or twice weekly (e.g., 1–2 mg subcutaneous) due to extended half-life.
  • Common stack: 100–200 mcg CJC-1295 (no DAC) + 200–300 mcg Ipamorelin nightly.
• Cycles: Often 8–12 weeks on, with breaks; monitor IGF-1 levels.

Potential Side Effects

Generally well-tolerated, especially compared to direct hGH:

• Common/mild: Injection-site reactions (redness, swelling, irritation), flushing, temporary water retention/edema, headaches, or mild nausea.
• Less common: Fatigue, dizziness, increased heart rate (more noted with DAC in some reports), or flu-like symptoms.
• Rare: Potential for elevated IGF-1 if overdosed (monitor labs); minimal impact on cortisol/prolactin/ACTH.
• Long-term data limited; side effects often dose-dependent and transient.

Note: Evidence is strongest from early human trials (e.g., dose-dependent GH/IGF-1 increases lasting days to weeks) and off-label/clinical observations. Large-scale Western RCTs for adult wellness uses are limited. Quality varies with suppliers—prioritize those with third-party testing/COAs.

Always consult a qualified healthcare professional before considering CJC-1295 or any peptide. Individual responses depend on age, baseline GH/IGF-1, and health; professional monitoring (e.g., bloodwork for IGF-1, glucose) is essential. Compared to Ipamorelin (a GHRP for rapid pulses, from your prior question) or Sermorelin (shorter GHRH analog), CJC-1295 offers more sustained GH elevation—especially with DAC—and is frequently stacked for optimal results. Let me know if you’d like details on stacks (e.g., with Ipamorelin), costs, or comparisons!